Cranial Placode Differentiation via Timed Dual-SMAD Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of understanding in human neural development and a need for inducing human floor plate tissue from human embryonic stem cells for medical research and treatment of developmental diseases.
Innovation Solution
A dual-SMAD inhibition strategy is used to derive cranial placodes from human pluripotent stem cells, which can generate trigeminal ganglia, mature lens fibers, and anterior pituitary hormone-producing cells through specific culture conditions and factors like brain-derived neurotrophic factor, sonic hedgehog, and γ-secretase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional differentiation methods are used for human stem cells, then the process is simple, but human floor plate tissue cannot be effectively produced
Solution Approach 1:
The patent applies parameter changes by systematically manipulating signaling pathway inhibitors (SMAD1/5/8 and SMAD2/3 inhibitors) at different concentrations and timing during differentiation. This creates specific parameter conditions that enable reliable production of human floor plate cells while maintaining protocol feasibility through defined parameter ranges.
Solution Approach 2:
The patent uses signaling pathway inhibitors as intermediary substances to mediate the differentiation process. These inhibitors act as intermediaries between the stem cells and the desired floor plate fate, enabling precise control over cell fate determination without direct genetic modification.
2Reliability
If dual-SMAD inhibition strategy is applied, then human floor plate tissue can be generated, but the protocol complexity increases
Solution Approach 1:
The patent segments the differentiation protocol into distinct temporal phases: early differentiation stage with SMAD1/5/8 inhibition, followed by a transition phase, and final floor plate specification with SMAD2/3 inhibition. This segmentation makes the complex dual-inhibition strategy manageable and reproducible by breaking it into discrete, controllable steps.
Solution Approach 2:
The patent applies preliminary action by first establishing neural progenitor cells through initial SMAD inhibition before introducing the second SMAD inhibition pathway. This staged approach ensures that cells are prepared for subsequent differentiation steps, making the overall protocol more manageable and reliable.
3Adaptability or versatility
If human floor plate cells are produced for therapeutic applications, then treatment possibilities expand, but cell production capability is currently insufficient
Solution Approach 1:
The patent generates universal human floor plate cells that can differentiate into multiple cell types including neurons, glial cells, and other neural elements. This multi-functionality enables a single cell type to address various therapeutic needs, expanding adaptability while maintaining controlled production through standardized differentiation protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of human neural cells for cell-based therapies in sensory and endocrine diseases, providing a source for medical research and therapeutic applications.
Implementation Method 1
a dual-SMAD inhibition strategy of neural induction coupled with further fate specification at the pre-placode stage
Implementation Method 2
contacting said plurality of placodal precursor cells with a composition comprising brain-derived neurotrophic factor, wherein a plurality of trigeminal placode cells are created
Implementation Method 3
sonic hedgehog (SHH) is a ventralizing factor acting in a dose-dependent manner to specify the various ventral cell types
Implementation Method 4
contacting said plurality of placodal precursor cells with a composition comprising sonic hedgehog, purmorphamine and a γ-secretase inhibitor, wherein a plurality of pituitary placode cells are created
Data Source
AI summary
Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.